Abstract: ObjectiveTo investigate the efficacy and tolerability of dosedense chemotherapy with cisplatin plus 5fluorouracil (PF regimen) in distant metastatic nasopharyngeal carcinoma (NPC) patients. MethodsFrom April 1, 2008 to April 30, 2014, 168 patients were assigned to traditional group (n=83) and dosedense group (n=85) using digital random table in 1∶1 ratio. All patients received PF regimen, and once every 28 days in traditional group and once every 14 days in dosedense group. The primary endpoint was progressionfree survival (PFS) and the secondary endpoint was overall survival (OS), toxicity and response rate. ResultsThe median PFS, median OS, 1, 2, 3year survival rate, complete response rate and objective response rate were significantly improved in dosedense group which were 13.3 months, 20.2 months, 80.2%, 36.0%, 16.1%, 16.5%, 84.7%, and those in control group were 10.0 months, 16.1 months, 59.6%, 10.1%, 0, 3.6%, 54.2% respectively (χ2＝24.47, P=0.000; χ2＝16.65, P=0.000; χ2＝8.41, P=0.004; χ2＝16.96, P=0.000; χ2＝14.91, P=0.000; χ2=7.63, P=0.006; χ2=18.47, P=0.000). The rates of grade 34 adverse events in dosedense and traditional group were 38.8% and 6.0% (χ2=25.81, P= 0.000). ConclusionDosedense chemotherapy of PF is more efficient and acceptable toxic than the traditional one. It can be a new treatment option for patients with distant metastases of NPC.

Key words: Nasopharyngeal neoplasms, Drug therapy, Dosedense